Gemphire Therapeutics Inc. (NASDAQ: GEMP) Starts Presentation at the 8th Annual LD Micro Invitational
Gemphire Therapeutics Inc. (NASDAQ: GEMP) is a clinical-stage biopharmaceutical company that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH. The company is focused on providing new treatment options for cardiometabolic diseases through its complementary, convenient, cost-effective product candidate gemcabene as add-on to the standard of care, especially statins, that will benefit patients, physicians, and payors. For more information, visit the company's website at www.Gemphire.com. About NetworkNewsWire NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social…







